NOTCH2 Monoclonal Antibody (16F11), PE, eBioscience™, Invitrogen™

Description

• Description: This 16F11 monoclonal antibody reacts with the extracellular domain of human and mouse Notch2, one of four members of the Notch family of receptors
• Notch receptors are 300-kDa single-pass transmembrane proteins
• While the extracellular domain contains numerous epidermal growth factor-like repeats for ligand binding, the intracellular domain is involved in cell signaling
• Upon binding its membrane-bound ligand (either Delta or Jagged), the Notch receptor undergoes proteolytic cleavage, first by ADAM-family metalloproteases and then by gamma-secretase
• The second cleavage event releases the Notch intracellular domain (NICD), which subsequently translocates into the nucleus, heterodimerizes with the DNA-binding protein RBP-J, recruits co-activator molecules, and ultimately activates transcription
• Notch2 is expressed on thymocytes (i.e., DN1 and DN2 subsets), activated peripheral T cells, and bone marrow
• Moreover, expression of Notch2 has been reported to be altered in various cancers and lymphomas
• In addition to its role in stem cell hematopoiesis, Notch2 plays a pivotal role in marginal zone B cell development
• Notch2 also interacts with phosphorylated CREB1 to induce granzyme B transcription in cytotoxic T cells
• Applications Reported: This 16F11 antibody has been reported for use in flow cytometric analysis
• Applications Tested: This 16F11 antibody has been tested by flow cytometric analysis of 24-hour anti-CD3-stimulated mouse splenocytes
• Neurogenic locus notch homolog protein 2 (NOTCH2) is a highly conserved Notch signaling pathway protein
• NOTCH2 is a type 1 transmembrane protein with an extracellular domain consisting of multiple epidermal growth factor-like (EGF) repeats, and an intracellular domain consisting of multiple, different domain types
• NOTCH2 functions as a receptor for membrane-bound ligands Jagged1, Jagged2 and Delta1 to regulate cell-fate determination
• Defects in NOTCH2 are the cause of Alagille syndrome type 2 (ALGS2)
• Alagille syndrome is an autosomal dominant multisystem disorder defined clinically by hepatic bile duct paucity and cholestasis in association with cardiac, skeletal, and ophthalmologic manifestations
• There are characteristic facial features and less frequent clinical involvement of the renal and vascular systems.